PHYSIQ 360 offers technological advancements that uniquely meet today's needs within the category MELVILLE, N.Y., April 25, 2024 /PRNewswire/ -- Cartessa Aesthetics, a premier North American aesthetic medical device company, launches PHYSIQ 360, a groundbreaking technology that elevates non-invasive body contouring. PHYSIQ 360 is the next generation of the award-winning PHYSIQ body technology that exemplifies the innovative partnership between Cartessa and DEKA, a leading global aesthetic lase

KENNEDY SPACE CENTER, Fla., April 25, 2024 /PRNewswire/ -- Arthritis is a crippling disease, affecting approximately one in four adults. It wreaks havoc on our joints by breaking down cartilage, the cushioning between bones. Once that cartilage deteriorates, there's no way to replace it. However, all this might soon change, thanks to a new investigation led by biomedical engineering researchers at the University of Connecticut. Continue Reading Yupeng Chen, an associate professor for biomedical

Planning enters next phase as ABMS announces open comment period WASHINGTON, April 25, 2024 /PRNewswire/ -- Efforts by the American College of Cardiology, the American Heart Association, the Heart Failure Society of America, the Heart Rhythm Society and The Society for Cardiovascular Angiography & Interventions to create a new, independent Board of Cardiovascular Medicine under the American Board of Medical Specialties (ABMS) are closer to becoming a reality with the creation of a formal Board o

– Company creating de novo designed macrocycles with enhanced efficacy that precisely target disease biology – Vilya’s privileged macrocycles have the potential to be applied across broad therapeutic areas, addressing large unmet medical needs SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely targets disease biology, today announced the publication of a new study in Science that validates the company’s fo

CBL-514 is the first product to treat cellulite at the raised areas. Currently, there is no effective and safe cellulite treatment on the market. The global market for cellulite treatment is estimated to expand to $7.37 billion in 2034. CBL-0201EFP Phase 2 study demonstrated CBL-514 statistically significant efficacy in reducing cellulite severity scores at 4 and 12 weeks after treatment. Over 50% of participants experienced at least one level of improvement in cellulite severity 12 weeks after

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on April 25, 2024, from Atlas Special Opportunities, LLC indicating that as of April 19, 2024, it held 380,755,774 shar

忆江南三月半，顺水下扬州。春色满园同写意，夹墙斜出绿枝头。佳处合淹留。——同写意参会嘉宾：石语又是一年春，同写意再赴扬州之约。4月25日，“2024扬州生物医药产业创新发展大会”再度启航！本次大会由扬州市人民政府主办，扬州市邗江区人民政府、扬州高新技术产业开发区管委会承办，由中国医药企业管理协会新药研发与注册专委会、江苏省药学会、扬州市市场监督管理局、扬州市科学技术局、扬州市科学技术协会协办，同写意倾心策划打造。大会以“打造生物医药新质生产力”为主题，同时开设创新药立项，资本寒冬下的创新药BD与出海，抗体药物质量与生产，以及GLP-1药物创新与发展四大主题会议，邀请了众多行业领袖和先锋人物展开深度研讨，一起取势明道，为行业发展提供方向性指引。其中，同写意就创新药立项与创新药BD与出海两个主题会议进行整理报道，让诸多的从业人员，也能在第一时间共享这一场行业盛宴，共合作，赢未来！开幕式及主旨会议领导致辞孙咸泽中国药学会理事长当前，全球生物医药领域正处于创新理念的重大变革期，基于还原科学论的药物研发模式难以满足临床复杂疾病治疗需求，全球新药研发的投入/产出比呈现出指数级的上涨态势。作为国家战

Q1 2024 revenue Quarterly activity Revenue: €194.3m, up 8.8% at CER1Growth remains particularly strong in Asia (+26.8% at CER) and the Americas (+20.1% at CER); the EMEA region (-6.2% at CER) was temporarily impacted by the reform of the supply of contrast products in France Annual targets confirmed Revenue: expected growth of over 8% like-for-like and at CERProfitability: restated EBITDA margin rate2 higher than in 2021 (14.4%) Villepinte, 25 April 2024, 5.45 pm: Guerbet (FR0000032526 G

Leading Breast AI Company, creator of industry-leading Transpara®, promotes from within for new CEO NIJMEGEN, Netherlands, April 25, 2024 /PRNewswire/ -- ScreenPoint Medical, today announced a significant transition in its leadership as Mark Koeniguer, the current CEO, steps down from his position. Mark served as CEO since 2022 and was instrumental in ScreenPoint's commercial growth and success over the past 2 years. Continue Reading Pieter Kroese, CEO of ScreenPoint Medical The company's Board

FORT MYERS, Fla., April 25, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist and hematologist Ernesto Bustinza-Linares, MD is co-author of a recent abstract published in the American Society of Clinical Oncology Journal, JCO Precision Oncology, that uncovers a new testing method to determine personalized care options for patients with metastatic non-small cell lung cancer (NSCLC). Continue Reading FCS medical oncologist and hematologist Ernesto B